Trial Profile
A Japanese Phase 1 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma and Roll Over Study for Subjects Who Have Participated in ME-401-004 Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Zandelisib (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Kyowa Kirin
- 01 Dec 2022 Results published in the International Journal of Hematology
- 10 Dec 2021 Planned End Date changed from 30 Sep 2021 to 30 Sep 2024.
- 10 Dec 2021 Planned primary completion date changed from 30 Sep 2021 to 30 Sep 2024.